Back to Search Start Over

SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 - Preliminary version

Authors :
Bernauer, U.
Bodin, L.
Chaudhry, Q.
Coenraad, P.J.
Dusinska, M.
Ezendam, J.
Gaffet, E.
Galli, C. L.
Granum, B.
Panteri, E.
Rogiers, V.
Rousselle, Ch.
Stepnik, M.
Vanhaecke, T.
Wijnhoven, S.
Cabaton, N.
Koutsodimou, A.
Uter, W.
Goetz, N. Von
CEA- Saclay (CEA)
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)
Scientific Committee for Consumer Safety (SCCS) (SCCS)
Institut Jean Lamour (IJL)
Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)
Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)
Scientific Committee for Consumer Safety (SCCS, EC)
Gaffet, Eric
Source :
Scientific Committee for Consumer Safety (SCCS, EC)., 2022, Scientific Committee for Consumer Safety (SCCS, EC)
Publication Year :
2022
Publisher :
HAL CCSD, 2022.

Abstract

International audience; SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 - Preliminary versionU. Bernauer, L. Bodin, Q. Chaudhry, P.J. Coenraad, M. Dusinska, J. Ezendam, E. Gaffet, C. L. Galli, B. Granum, E. Panteri, V. Rogiers, Ch. Rousselle, M. Stepnik, T. Vanhaecke, S. Wijnhoven, N. Cabaton, A. Koutsodimou, W. Uter, N. von GoetzThe SCCS adopted this document by written procedure on 12 January 2022 (149 pages)Mise en ligne le 13 Janvier 2022https://ec.europa.eu/health/sites/default/files/scientific_committees/consumer_safety/docs/sccs_o_263.pdfSCCS members: U. Bernauer (Rapporteur Daidzein), L. Bodin, Q. Chaudhry (Rapporteur Genistein), P.J. Coenraads (Chairperson), M. Dusinska, J. Ezendam, E. Gaffet, C.L. Galli (Rapporteur Genistein), B. Granum, E. Panteri, V. Rogiers, Ch. Rousselle (Rapporteur Daidzein), M. Stepnik, T. Vanhaecke, S. WijnhovenSCCS external experts: N. Cabaton, A. Koutsodimou, W. Uter, N. von GoetzContact: SANTE-C2-SCCS@ec.europa.euOn request from: European CommissionSCCS Number: SCCS/1641/22Adopted on: 12 January 2022Conclusion of the opinion:(1) In light of the data provided and taking under consideration the concerns related to potential endocrine disrupting properties of phytoestrogens,(a) does the SCCS consider genistein safe when used in cosmetic products up to a maximum concentration of 0.007%?(b) does the SCCS consider daidzein safe when used in cosmetic products up to a maximum concentration of 0.02%?a) the use of genistein (CAS No 446-72-0, EC No 207-174-9) in cosmetic products up to a maximum concentration of 0.007% is safe.b) the currently available information is not sufficient to exclude the potential genotoxic effects of daidzein (CAS No 486-66-8, EC No 207-635-4). The SCCS is therefore not able to carry out risk assessment to conclude on the safety of the use of daidzein in cosmetic products. (2) Alternatively, according to the SCCS what is the maximum concentration of genistein and daidzein that is considered safe for individual and combined use in cosmetic products?/(3) Does the SCCS have any further scientific concerns with regard to the use of genistein and daidzein or other related phytoestrogens in cosmetic products?/Keywords: SCCS, revision, scientific opinion, genistein - (CAS No 446-72-0, EC No 207-174-9), daidzein - (CAS No 486-66-8, EC No 207-635-4), Regulation 1223/2009Opinion to be cited as:SCCS (Scientific Committee on Consumer Safety), scientific opinion on genistein and daidzein, preliminary version of 12 January 2022, SCCS/1641/22.

Details

Language :
English
Database :
OpenAIRE
Journal :
Scientific Committee for Consumer Safety (SCCS, EC)., 2022, Scientific Committee for Consumer Safety (SCCS, EC)
Accession number :
edsair.dedup.wf.001..fc64f847c7dc8615a66305a6262454ba